SEP 10, 2026 · PHASE 2 TRIAL
Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment
ClinicalTrials.gov
This is a Phase 2 trial registration with no posted results; it describes a planned study in a rare population (transformed SCLC) using a combination of experimental and standard agents, based on mechanistic rationale and early-phase data from other cohorts.
Reported
Planned enrollment50
PhasePHASE 2
Primary outcome measureProgression-free survival (PFS) up to 6 mon…